Given that SFRP2 and THBS2 have a negative effect on CRC prognosis (Figure 4E,F), we constructed SFRP2 and THBS2 knockdown HCT116 cell lines and validated the knockdown efficacy at the mRNA (Figure 5C,D; Figure S1) and protein levels (Figure 5E–G). The gene discussed is SFRP2; the disease is colorectal carcinoma.